Ocular Therapeutix to Present Phase 3 SOL-1 OTX-TKI Data July 16 and Host Fireside Chat July 22
OCUL•Ocular Therapeutix will present detailed Phase 3 SOL-1 trial efficacy and safety data for its intravitreal axitinib hydrogel OTX-TKI in neovascular AMD at the ASRS annual meeting in Montreal on July 16. The company will also present at the OIS Retina Innovation Summit on July 14 and host a fireside chat at the HC Wainwright Ophthalmology Virtual Conference on July 22.
1. Scientific Conference Participation
Ocular Therapeutix will attend the OIS Retina Innovation Summit in Montréal on July 14 with a presentation titled “Retina Experience Redefined” by Chief Development Officer Peter K. Kaiser and will moderate a panel on recent FDA guidance impacts led by Executive Chairman Pravin U. Dugel. The company will also participate in the ASRS 44th Annual Meeting from July 15–18 in Montréal, featuring on-demand papers and symposia on anti-VEGF treatment patterns and sustained disease control.
2. Phase 3 SOL-1 OTX-TKI Trial Data
On July 16 at 8:15 AM EDT, Ocular’s Chief Development Officer Dilsher S. Dhoot will present phase 3 SOL-1 trial results for intravitreal axitinib hydrogel (OTX-TKI) in neovascular age-related macular degeneration, covering key efficacy and safety findings. Additionally, Andrew A. Moshfeghi will share real-world anti-VEGF utilization and vision outcomes, while Priya Vakharia provides IRIS Registry long-term outcomes in on-demand sessions.
3. HC Wainwright Investor Fireside Chat
Ocular Therapeutix’s Executive Chairman Pravin U. Dugel will host a virtual fireside chat at the HC Wainwright 6th Annual Ophthalmology Conference on July 22 from 4:30–5:00 PM EDT. A live webcast will be accessible on the company’s Investor Relations website, with a replay archived for at least 30 days after the presentation.
